Virginia finally has a retail cannabis market with a date attached to it. Applications open February 1, 2027. Sales begin July 1, 2027. That is the good news, and it comes with an uncomfortable corollary: everyone who wants a license is now working against the same calendar, and the ones who get there will be the ones who solved the money problem first. Funding a Virginia cannabis business is not the same exercise as funding an ordinary Virginia small business — the tax treatment is different, the lending market is different, the disclosure obligations run to every investor on your cap table, and you are raising against an application you have not yet won. This guide covers what you actually need to raise, where that money realistically comes from, how to structure it without creating a licensing problem, and what to do in the months between now and February.
Building a capital plan for a Virginia license application? We will pressure-test your use of funds, your pro forma, and your cap table against what the CCA will actually review.
Talk to Our TeamWhat's in this guide
- The Virginia calendar your raise has to fit
- How much you actually need
- Where the money comes from
- Structuring the raise
- The rules that constrain your cap table
- 280E, Virginia's decoupling, and the tax math
- What investors will diligence
- Raising against a license you don't have yet
- Hemp operators: the funding gap
- Six mistakes we keep seeing
- Your funding calendar to July 2027
- How Cannaspire helps
- Frequently asked questions
The Virginia calendar your raise has to fit
Capital plans fail on sequencing more often than on size. So start with the dates, because in Virginia they are unusually specific and they dictate when money has to be committed rather than merely discussed.
On June 29, 2026, the General Assembly enacted HB 30, the biennial budget bill, which carries the full legal framework for a commercial adult-use market. Retail sales begin July 1, 2027. The Cannabis Control Authority must adopt regulations by February 1, 2027 and begins accepting license applications on that same date. The Authority may begin issuing licenses on or after May 1, 2027.
| Date | What Happens | Capital Implication |
|---|---|---|
| August 15, 2026 | Virginia closes the 25:1 CBD-to-THC ratio allowance for regulated hemp products sold at retail, leaving a flat 2 mg total-THC-per-package ceiling | Hemp operators lose a revenue line roughly eleven months before licensed cannabis revenue is available |
| November 1, 2026 | CCA reports to the General Assembly on potential cultivation license limits and canopy adjustments | First real signal on cultivation scarcity — material to any cultivation pro forma |
| February 1, 2027 | Regulations adopted, application materials published, seed-to-sale system launched, applications open | Application fees, escrow or proof-of-funds requirements, and professional fees all land here |
| May 1, 2027 | Earliest license issuance. CCA awards up to 100 microbusiness licenses and a limited tranche of cultivation and processing licenses to qualifying pre-2021 hemp registrants | Buildout capital must be committed and callable, not "in discussion" |
| July 1, 2027 | Retail sales begin. Public consumption civil penalty rises to $250 | Working capital for inventory, payroll, and pre-revenue operations is consumed before the first dollar arrives |
| July 1, 2029 | State cannabis excise tax rises from 6% to 8% | Any five-year model needs the step-up built in, not bolted on |
Read the gap between February and July 2027 carefully. Five months separates the opening of applications from the opening of stores, and licenses may not issue until May. That means the money you raise in late 2026 has to survive an application period, a review period, a buildout, a seed-to-sale onboarding, and an inspection before it produces a single sale. Investors who have not funded a limited-license launch before consistently underestimate this window. Put it in the model in months, with a named funding source for each one.
How much you actually need
The honest answer in August 2026 is that nobody can quote you a total, because the CCA has not yet published application fees, license fees, or capitalization requirements — those come with the regulations due February 1, 2027. Anyone quoting you a precise all-in Virginia number today is extrapolating from other states.
What can be done now is to build the capital stack by category and put planning ranges on the lines that are knowable, then replace them with real figures as the CCA publishes. Here is the shape of it.
| Cost Category | What It Covers | Notes for Virginia |
|---|---|---|
| Application costs | Application fee, license fee, consulting and legal fees, application deliverables | Fees not yet published. Sunk whether or not you are awarded — budget them as expense, not investment |
| Site control | Lease deposits, option payments, purchase deposit, zoning and land-use work | Retail must sit at least 1,000 feet from schools, hospitals, playgrounds, and drug treatment facilities. Site diligence before signing, always |
| Buildout | Construction, security systems, HVAC and environmental controls for cultivation, fixtures, POS | The single largest line for most applicants, and the one most often underestimated on cultivation and processing projects |
| Compliance infrastructure | SOPs, seed-to-sale onboarding, training, testing relationships, security plan implementation | Virginia's seed-to-sale system launches with the regulations in February 2027 — onboarding is a real line item |
| Pre-revenue working capital | Payroll, rent, insurance, utilities, and inventory from license award to first sale | The line that kills otherwise sound plans. Size it from award to steady state, not to opening day |
| Conversion and entry fees | Statutory one-time fees for specific entry paths | Pre-2021 registered hemp growers and processors seeking the reserved cultivation or processing tranche face a one-time $500,000 fee, payable in installments over up to three years. Medical pharmaceutical processors seeking dual-use privileges face a one-time $10 million conversion fee or an approved installment plan by May 1, 2027 |
Those last two statutory figures are worth sitting with, because they tell you something about how Virginia has priced entry. A $500,000 conversion fee for an existing hemp operator, payable over three years, is a meaningful but survivable number for a real business. A $10 million dual-use fee is a number only an existing pharmaceutical processor will pay. Between them sits the microbusiness tier, capped at 5,000 square feet of indoor canopy or 10,000 outdoor, one license, up to two locations within twenty miles of each other. That tier exists specifically so the market is not decided entirely by balance sheet size — and it is the most realistic entry point for most Virginia entrepreneurs raising a first round.
Build the model in three scenarios, not one. Base case, delayed case, and denied case. The delayed case assumes license issuance slides a quarter and opening slides with it — perfectly plausible for a first-year program standing up a new tracking system. The denied case assumes you do not win and asks what the money bought: site option, entity, documentation, or nothing recoverable. Investors ask this question. Having the answer already written is worth more than a polished base case.
Where the money comes from
The financing market for cannabis is not the financing market for other businesses, and the difference is structural rather than a matter of sentiment. Nationally, debt has crowded out equity almost entirely: by one widely tracked count, debt accounted for roughly 95% of all capital raised by U.S. licensed operators in 2025. That figure describes mature operators refinancing existing paper, not first-time applicants — but it tells you where the professional money sits and how it prices risk.
| Source | How It Works in Practice | Realistic For |
|---|---|---|
| Founder and friends-and-family equity | The first money in nearly every Virginia application. Fastest to close, hardest to price fairly, most likely to create informal documentation problems later | Application-stage funding across all license types |
| Private equity from cannabis-specific investors | Funds and angels who already understand licensing risk and 280E. They price accordingly and often want board rights or protective provisions | Applicants with a credible team and a site, seeking $1M and up |
| Private debt and specialty lenders | Asset-backed or cash-flow lending at rates well above conventional commercial credit. Recent industry refinancings have priced in the low-to-mid teens | Post-award borrowers with collateral or contracted revenue — rarely pre-license |
| Real estate structures | Sale-leaseback or a landlord funding tenant improvements in exchange for a higher rent factor. Converts a capital problem into an operating expense problem | Applicants who own suitable real estate or can source a cannabis-friendly landlord |
| Equipment financing and vendor terms | Cultivation and processing equipment financed against the asset. Less dilutive than equity and easier to underwrite than an unsecured loan | Cultivation, processing, and testing applicants |
| Virginia Cannabis Equity Business Loan Fund | A state fund providing low-interest and zero-interest loans to qualifying social equity licensees. HB 30 directs 75% of first-year license fee revenue into it | Applicants who qualify for impact licensee status — see the eligibility caveat below |
| Revenue-based and non-dilutive alternatives | Royalty or revenue-share arrangements, brand licensing, management or services agreements | Operators with existing revenue elsewhere; use with care, see the ownership section |
What is missing from that table is conventional bank lending, SBA loans, and most institutional capital, because plant-touching cannabis remains federally illegal for adult-use purposes and those channels are effectively closed. That absence is the single biggest driver of cost of capital in this industry, and it is why a Virginia applicant's cost of capital will look nothing like a Virginia restaurant's.
The Equity Business Loan Fund deserves particular attention and particular caution. It is a genuine state-backed capital source, and it is being capitalized directly from early license fee revenue — which means the money arrives on roughly the same schedule as licensing. But it is available only to qualifying licensees, the detailed program mechanics come through CCA regulation, and lawmakers signaled that specific fund allocation rules would be finalized in a later session. Treat it as a real line in the plan if you qualify, and as a bridge rather than a foundation until the rules are published. If you think you may qualify, get the eligibility documentation assembled now — it is fact-specific and it takes longer than people expect.
Need a pro forma an investor and a scorer will both accept? Our cannabis business plan work produces documented assumptions, sensitivity cases, and a use-of-funds schedule built to the state's rubric.
Business Plans & Pro FormasStructuring the raise
Once you know roughly what you need and where it might come from, the structure question is what actually determines whether the raise helps or hurts your application. Four structures come up repeatedly.
Straight equity
Cleanest from a licensing standpoint, most expensive from a founder standpoint. Every equity holder above the CCA's disclosure threshold becomes part of your application file, which means every equity holder has to be diligenced by you before they are diligenced by the regulator. The practical discipline: a smaller number of larger, verifiable investors is easier to license than a long tail of small checks, even when the long tail is cheaper.
Convertible notes and SAFEs
Popular because they defer valuation, which is genuinely hard to set pre-license. The complication is that a note converting on a license award creates a contingent ownership change at exactly the moment the regulator is looking hardest at ownership. Conversion mechanics need to be drafted with the license in view, and the resulting cap table needs to be modeled and disclosed rather than discovered.
Debt
Non-dilutive and generally simpler to disclose, but pre-license debt is scarce because there is no collateral and no revenue. Where it exists, expect personal guarantees, short terms, and rates in the double digits. The question to ask of any pre-revenue debt is whether the amortization schedule starts before your revenue does. If it does, you have not solved a funding problem, you have moved it.
Management, services, and licensing agreements
This is the structure that gets applicants into trouble. Arrangements where an outside party funds the business and takes payment through a management fee, a services agreement, an IP royalty, or an aggressive supply contract are common in cannabis and are often used to keep a funder off the cap table. HB 30 gives the CCA explicit authority to investigate the ownership and control interests of licensees and to develop policies for auditing ownership and financial relationships across licensees. That is not incidental language. If an agreement gives someone economic control or operational control in substance, expect it to be evaluated as an ownership interest regardless of what the document is called.
Impact licenses carry a five-year holding period. The June 2026 compromise attached a five-year restriction on the sale or transfer of impact licenses, described by its authors as protection against predatory takeovers, along with limits on ownership transfers and anti-assignment rules. If your capital plan involves an outside investor acquiring control of an impact-designated license, or a structure that functions as a transfer without being called one, that plan does not work in Virginia. Build the impact structure with the holding period as a design constraint from the beginning, and have counsel review any investor agreement against it before it is signed.
The rules that constrain your cap table
In an ordinary business, who invests is your decision. In cannabis, it is partly the regulator's, and the specific constraints in Virginia are worth knowing before you take a check you cannot un-take.
- Full ownership disclosure. Beneficial owners must be disclosed to the CCA. Passive investors are not invisible investors. Every person on the cap table above threshold becomes part of the suitability review.
- Control audits. The Authority may investigate ownership and control interests and audit financial relationships across licensees. Undisclosed common control between applicants is a serious problem, and it is discoverable.
- Source of funds. Money that arrived informally, from unregistered investors, in cash, or from offshore accounts is a disclosure problem in cannabis even where it was unremarkable elsewhere. Clean the cap table before you file, not during review.
- License caps and phasing. Retail is capped at 350 statewide and will be phased in based on demand and geographic balance as the CCA determines. An investor thesis that assumes you can simply add stores needs to be tested against the cap and the phasing.
- Impact transfer restrictions. The five-year holding period and anti-assignment rules limit what an investor in an impact-designated license can be promised in terms of exit.
- Securities law. Raising money from outside investors is a securities offering whether or not anyone calls it one. Exemption selection, subscription documents, and disclosure of licensing risk are work for securities counsel, and doing it properly is cheaper than remediating it.
The operating principle we give clients is simple: assume every dollar you accept will be read aloud by a regulator. If a funding arrangement only works when nobody looks closely at it, it does not work.
280E, Virginia's decoupling, and the tax math
Any serious Virginia cannabis investment conversation reaches tax treatment within about ten minutes, because it changes returns more than any operating assumption. As of August 2026 the picture is genuinely split, and getting the split right in the model matters.
Federally, the Department of Justice issued a final order in April 2026 moving FDA-approved cannabis products and state-licensed medical cannabis from Schedule I to Schedule III, effective April 28, 2026. For those activities, Section 280E no longer applies. Adult-use cannabis did not move. It remains Schedule I, and 280E continues to disallow ordinary business expense deductions for adult-use operations at the federal level — leaving cost of goods sold as the principal deduction. Since Virginia's new market is an adult-use market, the base case for a Virginia applicant is that 280E applies federally.
At the state level, Virginia has decoupled. Licensed cannabis businesses may deduct ordinary and necessary business expenses on the Virginia return even where the federal deduction is disallowed. That is a real and quantifiable benefit, and it is one of the more investor-friendly features of the Virginia framework — but it operates on state income tax only, which is the smaller of the two numbers.
Then there is the consumer-facing tax stack, which shapes your revenue assumptions rather than your deductions: a 6% state cannabis excise tax rising to 8% after July 1, 2029, layered on top of Virginia's retail sales and use tax, plus an optional local tax of 1% to 3.5%. Depending on locality, the combined rate lands in the low-to-mid teens as a percentage of retail price. That is moderate by national standards and it matters competitively, because Virginia will be competing against an established illicit market and against neighboring states.
What to do with this in the model. Run federal 280E as the base case for adult-use, take the Virginia deduction where it applies, and treat any broader federal rescheduling of adult-use cannabis as upside rather than as an assumption. Show investors both cases explicitly. An applicant who models the optimistic case only is telling a sophisticated investor something unintentional about their judgment. We are consultants rather than tax advisors — the numbers in your pro forma should be confirmed by a qualified cannabis tax professional before they go into an offering document.
What investors will diligence
Investors who have funded cannabis before ask a consistent set of questions, and most of them are about de-risking the license rather than about the market opportunity. The market opportunity in a state of 8.7 million people with no legal retail channel is not the hard part to argue.
| What They Ask | What They Are Really Testing |
|---|---|
| Do you have site control, and is the site eligible? | Whether the plan is real. A signed option or lease on a site that clears the 1,000-foot buffer and local zoning is the single most convincing artifact an applicant can hold |
| Who has actually operated a licensed cannabis business? | Team credibility. Hemp experience, retail experience, and agricultural experience all help, but named operating experience under a cannabis license is what reduces perceived execution risk |
| Show me the use of funds by month | Whether you understand the award-to-revenue gap. A single lump-sum use of funds signals you have not modeled the sequence |
| What does the application actually score on? | Whether you have read the framework or the press coverage. Application materials publish February 1, 2027 — before then, the honest answer is a plan for how you will respond, not a claim about the rubric |
| What is the local government posture? | Political risk. Localities cannot opt out of the market entirely, but zoning, permitting, and community reception still decide whether a specific store opens on time |
| What happens if you don't win? | Downside protection. Have a written answer covering recoverable assets, reapplication in a later phase, and any alternative use of the entity or site |
Raising against a license you don't have yet
Here is the structural awkwardness of cannabis capital raising in Virginia right now: the money is needed before the license exists, and the license is not guaranteed. Retail is capped at 350 and phased. Microbusiness licenses are capped at 100 before May 1, 2027. Demand will exceed supply, and where a limited-license state has more qualified applicants than licenses, selection mechanisms — scoring, phasing, and in some structures a lottery element — decide outcomes that money alone cannot.
Three principles keep applicants out of trouble here.
- Never promise a license. Not in a pitch deck, not in a subscription agreement, not verbally. Represent the probability honestly and put licensing risk in writing in the offering materials. This is a securities law issue as much as an ethical one.
- Tranche the money to the milestones. Application-stage capital, award-contingent capital, and buildout capital should be separate commitments with defined triggers. Raising the full amount up front means burning buildout money on an application period, and raising only application money means having nothing callable when the award arrives.
- Make the recoverable assets explicit. A site option, a formed and documented entity, an SOP library, a completed business plan, and an assembled team have value in a later application phase or in a different market. Naming what survives a denial is how you make a contingent bet fundable.
February 1, 2027 is closer than a capital raise
Application-stage money takes months to close, and the deliverables it funds take months to build. Our Virginia cannabis consulting team maps your capital plan, your site, and your license target against the CCA's actual calendar — and tells you plainly when the right move is to aim at a later phase.
Schedule a Free ConsultationHemp operators: the funding gap
Virginia's hemp businesses face a version of this problem with a harder edge, and it is worth treating separately because the arithmetic is unforgiving.
As of August 15, 2026, the 25:1 CBD-to-THC ratio allowance closed for regulated hemp products sold at retail, leaving a flat 2 mg total-THC-per-package ceiling. For many Virginia hemp retailers and manufacturers, a substantial share of the catalog lost its legal channel on that date. Licensed cannabis retail does not begin until July 1, 2027. That is roughly eleven months of gap, and it sits directly on top of the period when application and buildout capital needs to be assembled.
Virginia did write an on-ramp into HB 30. Industrial hemp growers and processors registered with the Department of Agriculture and Consumer Services before January 1, 2021 may access a reserved tranche of up to ten cultivation and up to ten processing licenses, conditioned on a one-time $500,000 fee that the Board must allow to be paid in installments over up to three years. A streamlined application process for that track is due by February 1, 2027, and pre-2021 registrants in good standing may also be eligible for the microbusiness tranche. That is a genuinely favorable pathway — but it is narrow, it is capped, and it costs half a million dollars during a period when hemp revenue has already contracted.
The installment plan is the point. If you are a pre-2021 registrant considering the reserved tranche, the fact that the $500,000 fee can be spread across up to three years changes the financing question substantially — it converts a large capital requirement into a serviceable obligation, which is a materially easier thing to fund. Confirm the terms and the eligibility criteria against the CCA's published process rather than a summary, and model the payment schedule against your gap-period cash flow before committing.
Six mistakes we keep seeing
- Raising one round instead of three. Application, award, and buildout are different risk profiles and should be different commitments. Collapsing them means either burning buildout capital on paperwork or having no callable money at award.
- Taking money that creates a licensing problem. A funder who insists on control through a side agreement is more expensive than a funder who takes disclosed equity, because the first one can cost you the license.
- Modeling revenue from the license date. Between May 1, 2027 and a functioning store sits buildout, tracking-system onboarding, staff training, and inspection. Every month in between is payroll with no sales.
- Signing a lease before checking eligibility. The 1,000-foot buffer from schools, hospitals, playgrounds, and drug treatment facilities plus local zoning disqualifies more sites than applicants expect. Two weeks of diligence prevents a dead deposit.
- Assuming the equity loan fund will cover the plan. It is real, it is meaningful, and its detailed mechanics are still being written. Qualify for it, plan around it, do not depend on it.
- Treating the pro forma as a sales document. Sophisticated cannabis investors have seen hundreds of optimistic decks. A model that shows the 280E base case, the delayed-launch case, and the denial case reads as competence rather than as weakness.
Your funding calendar to July 2027
Working backward from February 1, 2027, here is the sequence that keeps a raise ahead of the application rather than behind it.
| Window | Funding Work |
|---|---|
| Now – October 2026 | Decide the license target and tier. Form and document the entity. Assemble the team. Confirm site eligibility against buffers and local zoning before spending on site control. Begin impact-licensee eligibility documentation if applicable |
| September – November 2026 | Build the three-scenario financial model and the month-by-month use of funds. Engage securities counsel on structure and exemption. Set the tranche triggers |
| October 2026 – January 2027 | Close application-stage capital. Secure site control with an option or contingent lease rather than a full commitment. Watch the CCA's November 1 cultivation report if you are targeting cultivation |
| February 2027 | Regulations and application materials publish. Replace every placeholder fee and requirement in the model with the published figure. File. Circulate the revised model to award-contingent investors |
| February – May 2027 | Hold buildout capital committed and callable. Finalize contractor bids and equipment financing. Complete SOPs and prepare for seed-to-sale onboarding so the buildout clock starts on award day |
| May – July 2027 | On award: draw buildout capital, execute the lease, onboard tracking, hire and train, pass pre-license inspection. Working capital funds payroll and first inventory through opening |
How Cannaspire helps
Cannaspire's cannabis consultants have supported more than 475 successful license applications for 450+ clients across 35+ states and eight-plus countries since 2019. Virginia is one of our primary markets, and we have been tracking this framework through the veto, the compromise, and the budget enactment. We are not a broker-dealer and we do not raise money for clients — what we do is make the business fundable and the application competitive, which are the two things that determine whether a raise closes.
On a Virginia capital engagement, you can expect us to:
- Size the raise properly. A capital stack built line by line against the CCA's published requirements as they land, with planning ranges clearly labeled as ranges until the regulations replace them.
- Build the model investors and scorers both accept. A cannabis business plan and pro forma with documented assumptions, month-by-month use of funds across the award-to-revenue gap, and base, delayed, and denied scenarios.
- Pressure-test the structure. Review of proposed investor arrangements against Virginia's ownership disclosure, control audit, and impact transfer rules, so a funding decision does not become a licensing defect. We work alongside your securities and cannabis counsel rather than in place of them.
- Confirm site eligibility early. Buffer and zoning diligence before deposits, because a disqualified site is the most expensive avoidable mistake in this process.
- Prepare the compliance deliverables. SOPs, security plans, quality systems, and training programs written to Virginia's regulations and tracking system — the substantive parts of an application that cannot be compressed at the deadline.
- Stay on after the award. Buildout support, pre-license inspection preparation, and ongoing compliance so the license survives its first audit and the investment survives its first year.
Our Virginia cannabis consulting practice tracks license types, fees, and windows as the CCA publishes them, and you can follow the Authority's own announcements directly at the Virginia Cannabis Control Authority. We are consultants, not attorneys, tax advisors, or investment advisors — on questions requiring a licensed professional we will say so and work alongside yours.
475+ licenses won. Now building capital plans for Virginia.
Whether you are assembling a first round, evaluating an investor term sheet, or deciding between the microbusiness tier and a full retail application, start with an honest read of your numbers and your calendar.
Start the ConversationFrequently asked questions
How much capital do I need to open a cannabis business in Virginia?
When should I start raising money for a Virginia cannabis license?
Can out-of-state investors fund a Virginia cannabis business?
Is there state funding available for a Virginia cannabis business?
Does Section 280E apply to a Virginia cannabis business?
Can I promise investors that I will get a license?
Can I get a bank loan or an SBA loan for a Virginia cannabis business?
Should I raise equity or debt for a cannabis license application?
Can an impact licensee take outside investment?
How does the microbusiness tier change the funding math?
Make the numbers fundable before you make the pitch
A capital plan built on the CCA's actual calendar, an honest pro forma, and a cap table that survives a control audit. That is what closes a round in this market. Free 30-minute consultation, no commitment.
Talk to Our TeamPrimary sources
- Virginia HB 30, 2026–2028 biennial budget bill (enacted June 29, 2026), adult-use marijuana provisions
- Office of the Governor of Virginia, "Governor Spanberger, Senator Aird, & Delegate Krizek Announce Agreement to Create a Legal Retail Cannabis Market in Virginia" (June 16, 2026)
- Virginia Cannabis Control Authority and Virginia Department of Agriculture and Consumer Services, "Virginia's New Marijuana and Hemp Laws: What You Need to Know" (July 2026)
- Code of Virginia § 4.1-1501 and § 4.1-1502, Virginia Cannabis Equity Business Loan Program and Fund
- U.S. Department of Justice final order rescheduling FDA-approved and state-licensed medical cannabis to Schedule III (effective April 28, 2026)
- Viridian Capital Advisors Cannabis Deal Tracker, as reported by MJBizDaily, on the debt share of U.S. licensed-operator capital raises (March 2026)
Disclaimer: This article describes Virginia's adult-use cannabis framework as enacted in HB 30 and selected federal tax developments as of August 2026, and is a fast-moving subject. Cannabis Control Authority regulations, application materials, fee schedules, and capitalization requirements had not been published at the time of writing and are due by February 1, 2027; figures and requirements will change when they are published. Nothing here is legal, tax, securities, or investment advice, does not create a client relationship, and should not be relied upon in place of advice from a qualified attorney, tax advisor, or licensed investment professional regarding your specific facts. Cannaspire is a cannabis and hemp consulting firm; it does not practice law, provide tax opinions, offer investment advice, or act as a broker-dealer or placement agent. Last updated: August 19, 2026.